Ignite Creation Date:
2024-05-06 @ 2:24 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02031861
Status:
COMPLETED
Last Update Posted:
2015-02-05
First Post:
2014-01-08
Brief Title:
Efficacy Study of Nifedipine Controlled-Release Tablets Xin Ran to Treat Mild to Moderate Essential Hypertension
Sponsor:
Shanghai Shyndec Pharmaceutical Co Ltd
Organization:
Shanghai Shyndec Pharmaceutical Co Ltd
Study Overview
Official Title:
Random Open Label Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets Xin Ran in Patients With Mild to Moderate Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare nifedipine controlled-release CR tablets Xin Ran with nifedipine controlled-release tablets Adalatin the treatment of mild to moderate essential hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None